Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Past Earnings Performance
Past criteria checks 0/6
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's earnings have been declining at an average annual rate of -2.1%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 4.3% per year. Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's return on equity is 4.3%, and it has net margins of 12.6%.
Key information
-2.1%
Earnings growth rate
-6.2%
EPS growth rate
Pharmaceuticals Industry Growth | 5.6% |
Revenue growth rate | 4.3% |
Return on equity | 4.3% |
Net Margin | 12.6% |
Next Earnings Update | 15 Aug 2024 |
Recent past performance updates
Recent updates
What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend
Apr 12We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease
Mar 22Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Mar 07Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?
Feb 20Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?
Feb 07Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?
Jan 25Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?
Jan 12Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?
Dec 28Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly
Dec 15Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Dec 03Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 21Revenue & Expenses BreakdownBeta
How Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 809 | 102 | 428 | 253 |
31 Dec 23 | 851 | 109 | 450 | 244 |
30 Sep 23 | 1,023 | 191 | 539 | 223 |
30 Jun 23 | 1,283 | 242 | 694 | 242 |
31 Mar 23 | 1,080 | 142 | 630 | 233 |
31 Dec 22 | 1,031 | 138 | 597 | 227 |
30 Sep 22 | 1,158 | 132 | 739 | 237 |
30 Jun 22 | 1,013 | 112 | 650 | 229 |
31 Mar 22 | 1,155 | 213 | 675 | 227 |
31 Dec 21 | 1,140 | 213 | 666 | 224 |
30 Sep 21 | 1,036 | 198 | 579 | 196 |
30 Jun 21 | 997 | 201 | 554 | 183 |
31 Mar 21 | 925 | 188 | 524 | 167 |
31 Dec 20 | 834 | 165 | 482 | 139 |
30 Sep 20 | 901 | 191 | 524 | 135 |
30 Jun 20 | 874 | 165 | 522 | 131 |
31 Mar 20 | 980 | 204 | 622 | 146 |
31 Dec 19 | 1,029 | 227 | 588 | 128 |
30 Sep 19 | 848 | 151 | 509 | 130 |
30 Jun 19 | 837 | 151 | 526 | 122 |
31 Mar 19 | 678 | 91 | 397 | 92 |
31 Dec 18 | 742 | 112 | 486 | 114 |
30 Sep 18 | 632 | 95 | 395 | 112 |
30 Jun 18 | 521 | 78 | 305 | 110 |
31 Mar 18 | 510 | 77 | 306 | 110 |
31 Dec 17 | 498 | 75 | 308 | 110 |
30 Sep 17 | 575 | 109 | 355 | 105 |
30 Jun 17 | 652 | 142 | 403 | 99 |
31 Mar 17 | 637 | 141 | 395 | 97 |
31 Dec 16 | 622 | 139 | 386 | 95 |
30 Sep 16 | 615 | 136 | 372 | 104 |
30 Jun 16 | 607 | 134 | 359 | 113 |
31 Mar 16 | 593 | 131 | 348 | 112 |
31 Dec 15 | 579 | 128 | 338 | 110 |
30 Sep 15 | 556 | 125 | 333 | 112 |
30 Jun 15 | 532 | 122 | 327 | 114 |
31 Mar 15 | 501 | 120 | 304 | 109 |
31 Dec 14 | 471 | 118 | 281 | 105 |
30 Sep 14 | 464 | 111 | 269 | 105 |
30 Jun 14 | 412 | 96 | 243 | 79 |
31 Mar 14 | 446 | 98 | 271 | 69 |
31 Dec 13 | 416 | 87 | 253 | 68 |
30 Sep 13 | 367 | 76 | 221 | 57 |
30 Jun 13 | 307 | 65 | 186 | 52 |
Quality Earnings: 1349 has a large one-off gain of CN¥17.3M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 1349's current net profit margins (12.6%) are lower than last year (13.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1349's earnings have declined by 2.1% per year over the past 5 years.
Accelerating Growth: 1349's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1349 had negative earnings growth (-28%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (1.3%).
Return on Equity
High ROE: 1349's Return on Equity (4.3%) is considered low.